Description

This episode explores the latest developments in liver disease, with a focus on metabolic-associated steatotic liver disease (MASLD) and its impact on liver cancer, particularly hepatocellular carcinoma (HCC). The main focus is the emerging role of advanced imaging technologies. The discussion:

  • Compares traditional ultrasound with advanced imaging techniques.
  • Examines AI-based approaches in patient classification.

The episode concludes with a forward-looking perspective on the future management of MASLD.

Faculty

  • Thomas Berg (Moderator)
  • Timm Denecke (Faculty)
  • Juan-Manuel Pericàs (Faculty)
  • Valérie Vilgrain (Faculty)

This EASL Studio is supported by Bayer. EASL has received no input from Bayer with regards to the content of this programme.

Related episodes

ℹ️ Please click here to access the podcast version of this EASL Studio episode.

Log in to post comments